Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis

被引：54

作者：

Galvis, Marisol Miranda ^{[1
,2
]}

Borges, Gabriel Alvares ^{[2
,3
]}

de Oliveira, Thiago Bueno ^{[4
]}

de Toledo, Isabela Porto ^{[3
]}

Castilho, Rogerio Moraes ^{[2
,5
]}

Silva Guerra, Eliete Neves ^{[2
,3
]}

Kowalski, Luiz Paulo ^{[1
,6
,7
]}

Squarize, Cristiane Helena ^{[2
,5
]}

机构：

[1] Univ Campinas UNICAMP, Piracicaba Dent Sch, Oral Diag Dept, Piracicaba, Brazil

[2] Univ Michigan, Sch Dent, Lab Epithelial Biol, Dept Periodont & Oral Med, 1011N Univ Ave, Ann Arbor, MI 48109 USA

[3] Univ Brasilia, Hlth Sci Fac, Lab Oral Histopathol, Brasilia, DF, Brazil

[4] AC Camargo Canc Ctr, Clin Oncol Dept, Sao Paulo, Brazil

[5] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[6] AC Camargo Canc Ctr, Dept Head & Neck Surg & Otorhinolaryngol, Sao Paulo, Brazil

[7] Univ Sao Paulo, Med Sch, Head & Neck Surg Dept, Sao Paulo, Brazil

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 150卷

基金：

巴西圣保罗研究基金会;

关键词：

Head and neck squamous cell carcinoma; Immunotherapy; Human papillomavirus; Programmed death-ligand 1; Toxicity; Meta-analysis; SQUAMOUS-CELL CARCINOMA; METASTATIC HEAD; SINGLE-ARM; OPEN-LABEL; PEMBROLIZUMAB; RECURRENT; CHEMOTHERAPY; CETUXIMAB;

D O I：

10.1016/j.critrevonc.2020.102966

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Despite multiple modalities used to management of head and neck squamous cell carcinoma (HNSCC), disease control remains unsatisfactory. Immunotherapy is emerging as a novel therapeutic approach. This systematic review assesses clinical data regarding immunotherapy efficacy and safety. Methods: Data from 11 clinical trials testing immunotherapy in HNSCC were assessed. We performed the meta-analysis to correlate the overall survival (OS), response rate (RR), adverse effects, HPV status, and PD-L1 expression. Results: Immunotherapy extended OS (hazard ratio = 0.77, p < 0.0001) and RR significantly (risk ratio = 1.41, p = 0.02). Patients with HPV-positive HNSCC exhibited a better RR (risk ratio = 1.29, p = 0.24) and OS (11.5 vs. 6.3 months). PD-L1 positive tumors showed a higher OS (9.9 vs. 6.5 months). Moreover, immunotherapy caused less adverse effects than standard therapy. Conclusion: Our results indicate the benefit of immunotherapy for improving RR and OS of HNSCC patients. The benefit is higher in patients with HPV and PD-L1 positive tumors.

引用

页数：18

共 49 条

[1] Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].

Andre, Pascale ;

Denis, Caroline ;

Soulas, Caroline ;

Bourbon-Caillet, Clarisse ;

Lopez, Julie ;

Arnoux, Thomas ;

Blery, Mathieu ;

Bonnafous, Cecile ;

Gauthier, Laurent ;

Morel, Ariane ;

Rossi, Benjamin ;

Remark, Romain ;

Breso, Violette ;

Bonnet, Elodie ;

Habif, Guillaume ;

Guia, Sophie ;

Lalanne, Ana Ines ;

Hoffmann, Caroline ;

Lantz, Olivier ;

Fayette, Jerome ;

Boyer-Chammard, Agnes ;

Zerbib, Robert ;

Dodion, Pierre ;

Ghadially, Hormas ;

Jure-Kunkel, Maria ;

Morel, Yannis ;

Herbst, Ronald ;

Narni-Mancinelli, Emilie ;

Cohen, Roger B. ;

Vivier, Eric .

CELL, 2018, 175 (07) :1731-+

[2]

[Anonymous], 2018, JAMA ONCOL

[3]

[Anonymous], 2017, JOANNA BRIGGS I REVI

[4]

[Anonymous], J CLIN ONCOL

[5]

[Anonymous], GRADEPRO GDT GRADEPR

[6] GRADE guidelines: 3. Rating the quality of evidence [J].

Balshem, Howard ;

Helfand, Mark ;

Schuenemann, Holger J. ;

Oxman, Andrew D. ;

Kunz, Regina ;

Brozek, Jan ;

Vist, Gunn E. ;

Falck-Ytter, Yngve ;

Meerpohl, Joerg ;

Norris, Susan ;

Guyatt, Gordon H. .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (04) :401-406

[7] Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study [J].

Bauml, Joshua ;

Seiwert, Tanguy Y. ;

Pfister, David G. ;

Worden, Francis ;

Liu, Stephen V. ;

Gilbert, Jill ;

Saba, Nabil F. ;

Weiss, Jared ;

Wirth, Lori ;

Sukari, Ammar ;

Kang, Hyunseok ;

Gibson, Michael K. ;

Massarelli, Erminia ;

Powell, Steven ;

Meister, Amy ;

Shu, Xinxin ;

Cheng, Jonathan D. ;

Haddad, Robert .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) :1542-+

[8] Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis [J].

Baxi, Shrujal ;

Yang, Annie ;

Gennarelli, Renee L. ;

Khan, Niloufer ;

Wang, Ziwei ;

Boyce, Lindsay ;

Korenstein, Deborah .

BMJ-BRITISH MEDICAL JOURNAL, 2018, 360

[9]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[10] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

← 1 2 3 4 5 →